Drug Profile
Uridine triphosphate
Alternative Names: INS 316; INS 316 Diagnostic; KRN-316; Prolucin; UTPLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Inspire Pharmaceuticals; Kirin Brewery
- Class Diagnostic agents; Expectorants; Nucleosides; Small molecules
- Mechanism of Action Purinoceptor P2U agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bronchitis; Cystic fibrosis; Lung cancer; Primary ciliary dyskinesia
Most Recent Events
- 01 Jul 2003 Inspire is analysing phase III results with the aim to decide whether to terminate or continue the programme
- 15 Nov 2001 A study has been added to the Diagnostic Agents therapeutic trials and adverse events sections
- 28 Jun 2001 Genentech is no longer collaborating with Inspire Pharmaceuticals on pyrimidine Y2 agonist programmes